Bank of America Corp DE Has $558,000 Stake in Enanta Pharmaceuticals Inc (ENTA)

Bank of America Corp DE lifted its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 4.9% during the 4th quarter, Holdings Channel reports. The firm owned 7,876 shares of the biotechnology company’s stock after acquiring an additional 369 shares during the period. Bank of America Corp DE’s holdings in Enanta Pharmaceuticals were worth $558,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 64.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 249 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Enanta Pharmaceuticals by 33.0% during the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares during the last quarter. Xact Kapitalforvaltning AB boosted its holdings in shares of Enanta Pharmaceuticals by 36.0% during the fourth quarter. Xact Kapitalforvaltning AB now owns 3,400 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 900 shares during the last quarter. Piedmont Investment Advisors Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 3.4% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 3,762 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 125 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 17.9% during the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 4,290 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 650 shares during the last quarter. Institutional investors and hedge funds own 86.86% of the company’s stock.

Shares of ENTA opened at $90.01 on Monday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 25.86 and a beta of 1.30. Enanta Pharmaceuticals Inc has a twelve month low of $64.08 and a twelve month high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.29. The business had revenue of $39.60 million for the quarter, compared to analyst estimates of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The business’s quarterly revenue was down 10.0% on a year-over-year basis. During the same period last year, the company posted $0.61 EPS. As a group, analysts predict that Enanta Pharmaceuticals Inc will post 1.52 earnings per share for the current fiscal year.

Several equities research analysts have recently issued reports on ENTA shares. BidaskClub upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 24th. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Finally, Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Enanta Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $114.40.

In related news, Director Bruce L. A. Carter sold 1,546 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $99.16, for a total value of $153,301.36. Following the transaction, the director now directly owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Golumbeski sold 9,280 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $103.65, for a total value of $961,872.00. Following the completion of the transaction, the director now directly owns 9,280 shares in the company, valued at $961,872. The disclosure for this sale can be found here. Insiders sold a total of 20,826 shares of company stock worth $2,150,473 over the last ninety days. Corporate insiders own 11.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/20/bank-of-america-corp-de-has-558000-stake-in-enanta-pharmaceuticals-inc-enta.html.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.